<!doctype html>
<html>
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="chrome=1">
    <title>Prostate-cancer-screening-with-prostate-specific-antigen by openMetaAnalysis</title>

    <link rel="stylesheet" href="stylesheets/styles.css">
    <link rel="stylesheet" href="stylesheets/pygment_trac.css">
    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no">
    <!--[if lt IE 9]>
    <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->
<!-- Added these two js source files -->
<script src="//ajax.googleapis.com/ajax/libs/jquery/2.1.1/jquery.js"></script>
<script src="/openmetaanalysis.js"></script>
<link rel="stylesheet" href="/openmetaanalysis.css">
  </head>

  <body>
    <div class="wrapper">
      <header>
        <h1 class="repo_name"></h1>
        <p class="view">Short URL: <a href="https://openmetaanalysis.github.io/psa">openmetaanalysis.github.io/psa</a></p>
        <p class="view"><a href="" class="master-home">View the Project on GitHub (for authors)</a></p>
        <!--<ul>
          <li><a href="zipball/master" class="master">Download <strong>ZIP File</strong></a></li>
          <li><a href="tarball/master" class="master">Download <strong>TAR Ball</strong></a></li>
          <li><a href="" class="master">View On <strong>GitHub</strong></a></li>
        </ul>-->

      </header>
      <section>

<!-- **Edit here** -->
<p><strong>Clinical summary:</strong> 
This meta-analysis suggests that clinical intervention is effective. Metaregression indicates a correlation between the benefit of screening and years of coverage added by screening with the prostate-specific antigen. 
The optimal frequency of screening may be up to 2-4 years as this interval best explains the variation in the results of trials (<a href="https://github.com/openMetaAnalysis/Prostate-cancer-screening-with-prostate-specific-antigen/blob/master/metaregression/Outcome-Primary%20-%20varying%20assumptions.png">see analysis</a>). 
The number need to invite (NNI) to prevent one death from prostate cancer is 1000 among the subgroup of trials adding more than 3 years of monitoring and 194 in the older cohort within the Göteborg trial.
However, the quality of evidence for benefit from PSA screening for prostate cancer is <GRADE>moderate</GRADE> due to our retrospective identification of subgroups. 
Additional interpretations may be in the references in the 'Cited by' section below.</p>

<!-- Table of results; composed with https://www.tablesgenerator.com/html_tables-->
<table style="border-collapse:collapse;border-spacing:0" class="tg"><tr><th style="font-family:Arial, sans-serif;font-size:14px;font-weight:bold;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center">Number of years of<br/> screening coverage added</th><th style="font-family:Arial, sans-serif;font-size:14px;font-weight:bold;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">Relative risk<br/>(estimated*)</th><th style="font-family:Arial, sans-serif;font-size:14px;font-weight:bold;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:left;vertical-align:top">Number needed to screen<br/>(based on control rate of<br/>4 deaths per 1000 men across all trails)</th></tr>
  <tr><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">3.2</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">0.93</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:left;vertical-align:top">357</td></tr><tr><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">3.5</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">0.84</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:left;vertical-align:top"></td></tr><tr><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">3.8</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">0.68</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:left;vertical-align:top"></td></tr><tr><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">4.0</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:center;vertical-align:top">0.53</td><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:left;vertical-align:top"></td></tr>
  <tr><td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:inherit;text-align:left;vertical-align:top" colspan="3">*Estimates are based on non-linear exponential meta-regression in the figure below.</td></tr></table>
        
<CRITERIA>We included trials of screening for prostate cancer with serial testing of levels of prostate-specific antigen.</CRITERIA>
<!-- **to here** -->

<ul>
<li><a href="reconciliation-tables/Reconciliation of conclusions.pdf" class="master-dir" title="Table in PDF format">Reconciliation of conclusions with prior meta-analyses</a> (<a href="reconciliation-tables/Source" class="master-dir">source files</a>)</li>
<li>
<script>
document.write('<a href="https://github.com/openMetaAnalysis/' + repo_dir + '/blob/master/files/searching/Keep-up.md">Keep current with this topic</a>')
</script>
</li>
</ul>
<p>Acknowledgement: we acknowledge the essential work by the authors of the prior systematic review(s) listed below.</p>

<p><strong>Methods overview:</strong> This repository is an <a href="https://openmetaanalysis.github.io/">openMetaAnalysis</a> that combines methods of scoping, rapid, and living systematic reviews. This analysis updates one or more previously published review(s)(<a href="#Prior_systematic_reviews">1</a>).</p>
<p><span id="criteria_display">&nbsp;</span> Newer studies included are listed in the <a href="#Studies">references</a>. Rationale for newer trials excluded may be listed at the end of the references.</p>
<ul>
<script>
document.write('<li><a href="https://github.com/openMetaAnalysis/' + repo_dir + '/blob/master/files/searching/evidence-search.md">Evidence search for this review</a> (under construction)</li>')
</script>
</ul>
<p>A comparison of studies included in this review compared to prior reviews are in the table, <a href="reconciliation-tables/Reconciliation of studies.pdf" class="master-dir" title="Table in PDF format">reconciliation of studies included with prior meta-analyses</a>. Studies were abstacted into standardized tables of <script>document.write("<a href='https://github.com/openMetaAnalysis/" + repo_dir + "/blob/master/files/study-details/table-pico.pdf'>PICO attributes</a> and <a href='https://github.com/openMetaAnalysis/" + repo_dir + "/blob/master/files/study-details/table-bias.pdf'>risk of bias</a>")</script>, and <a href="data/" class="master-dir" title="data files">results</a>.</p>
<ul>
<li><a href="/methods.html">Methods for openMetaAnalysis</a></li>
</ul>

<p><strong>Results:</strong> Details of the studies included are in the:</p>
<ul>
<li><a href="PRISMA/" class="master-dir">PRISMA documentation</a></li>
<li><a href="reconciliation-tables/" class="master-dir">Reconciliation of studies included with other meta-analyses</a></li>
<li><a href="table-pico.html">PICO table</a></li>
<li><a href="table-bias.html">Risk of bias table</a></li>
<li><a href="https://github.com/openMetaAnalysis/Prostate-cancer-screening-with-prostate-specific-antigen/issues/6">Calculations and plots of years of monitoring added by screening in each trial</a></li>
<li><a href="forest-plots/" class="master-dir">Forest plot(s)</a> (<a href="data/" class="master-dir">source data</a>)</li>
<li><a href="https://github.com/openMetaAnalysis/Prostate-cancer-screening-with-prostate-specific-antigen/wiki/Prostate-Facts-%28patient-information-handout%29">Prostate Facts (patient information handout)</a></li>
</ul>

<p>The forest plot for the primary outcome is below. Additional <a href="forest-plots/" class="master-dir" title="forest plots">forest plots of secondary analyses</a> may be available.</p>
<a href="forest-plots/Outcome-Primary.png" class="master-file"><img src="forest-plots/Outcome-Primary.png" alt="Image of forest plot of primary outcome" title="Principal results" style="max-width:100%;" class="master" id="forest"></a>

<div id="metaregression" style="display:none">
<div>The metaregression for the primary outcome is below. Additional <a href="metaregression/" class="master-dir" title="metaregressions plots">metaregression plots</a> may be available.</div>
<a href="metaregression/Outcome-Primary.png" class="master-file"><img src="metaregression/Outcome-Primary.png" alt="Image of meta-regression of primary outcome" title="Principal results" style="max-width:100%;" class="master" id="metaregression_figure"></a>
</div>

<p>The <SoF>Summary of Findings Table (SoF)</SoF> from the GRADE Profile is below (<a href="GRADE-profiles/" class="master-dir" title="GRADE Profiles">source files</a>).
<a href="GRADE-profiles/Summary-of-findings-table.png" class="master-file"><img src="GRADE-profiles/Summary-of-findings-table.png" alt="Image of GRADE Profile of primary outcome" title="Principal results" style="max-width:100%;" class="master" id="grade"></a></p>

<div id="references"><h2>References:</h2>

<a id="Prior_systematic_reviews"><h3>Systematic review(s)</h3></a>
<!-- **Edit the most current review here** -->
<h4>Most recent review at time of last revision of this repository</h4>
<ol>
  <li>Canadian Task Force on Preventive Health Care, Bell N, Connor Gorber S, Shane , Joffres M, Singh H, Dickinson J, Shaw E, Dunfield L, Tonelli M. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186(16):1225-34. doi: 10.1503/cmaj.140703. PMID: 25349003; PMCID: PMC4216256</li>
  <li>Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158(10):761-9. doi: 10.7326/0003-4819-158-10-201305210-00633. PMID: 23567643.</li>
  <li>Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. PMID: 23440794</li>
  <li>Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. PMID: 21984740.</li>
</ol>

<a id="Studies"><h3>Randomized controlled trials</h3></a>

<h4>New trial(s) <em>not</em> included in the most recent review above</h4>
<!-- **Edit new original studies here** -->
<ol>
<li>None</li>
</ol>
<!-- **to here** -->
</ol>

<h4>Trials included</h4>
<ol>
<!-- **Edit references here** -->
<li>Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011;342:d1539. doi:10.1136/bmj.d1539. PMID: 21454449; PMCID: PMC3069219</li>
<li>Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. PMID: 20598634; PMCID: PMC4089887</li>
<li>Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8. doi: 10.1056/NEJMoa0810084. PMID: 19297566</li>
<li>Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9. doi: 10.1056/NEJMoa0810696. PMID: 19297565; PMCID: PMC2944770</li>
<li>Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3):311-8. PMID: 15042607</li>
<!-- **to here** -->
</ol>

<h4>Studies undergoing review</h4>
<ol>
<!-- **Edit references here** -->
<li>Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519. PMID: 30185521</li>
<li>1: Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712. PMID: 29801018.</li>
<li>Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al; CAP Trial Group. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.  PMID: 29509864.</li>
<li>Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al; ERSPC investigators. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019 Feb 26. pii: S0302-2838(19)30150-2. doi: 10.1016/j.eururo.2019.02.009. PMID: 30824296.</li>
<!-- **to here** -->
</ol>

<h4>Trials excluded - selected list of important trials</h4>
<!-- **Edit excluded studies here** -->
<ol>
<li>Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol. 2009 Apr;181(4):1615-21; discussion 1621. doi: 10.1016/j.juro.2008.11.115. PMID: 19233435<br/>Excluded as intervention included both PSA, rectal examination, and prostate ultrasound.</li>
<li>Lundgren PO, Kjellman A, Norming U, Gustafsson O. Long-term outcome of a single intervention Population based Prostate Cancer Screening Study. J Urol.
2018 Jan 31. pii: S0022-5347(18)30173-3. doi: 10.1016/j.juro.2018.01.080. PMID: 29408619.<br/>This is the long-term follow-up to the Kjellman report.</li>
<!-- **to here** -->
</ol>

<h4>Funding for this review</h4>
<!-- **Edit excluded studies here** -->
<ol>
<li>None.</li>
</ol>

<h4>Cited by</h4>
<p>This repository is cited by:</p>
<ol>
<!-- Edit cited by references below this line -->
<li>Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5;362:k3519. doi:
10.1136/bmj.k3519. PMID: 30185521</li>
<li>Rahal AK, Badgett RG, Hoffman RM. Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review. PLoS One. 2016 Apr
12;11(4):e0153417. doi: 10.1371/journal.pone.0153417. PMID: 27070904; PMCID: PMC4829241.</li>
<li>WikiDoc contributors. Prostate Cancer Screening. WikiDoc. June 14, 2015. Available at: <a href="http://www.wikidoc.org/index.php/Prostate_cancer_screening">http://www.wikidoc.org/index.php/Prostate_cancer_screening</a>. Accessed June 14, 2015. </li>
</ol>
</div>
<!-- End of references. PMIDs and PCMIDs are make into links-->
</section>

<footer>
<p>This project is maintained by <a href="http://openmetaanalysis.github.io/">openMetaAnalysis</a></p>
<p><small>Hosted on GitHub Pages &mdash; Theme by <a href="https://github.com/orderedlist">orderedlist</a></small></p>
<div id="business"></div>
</footer>
</div>

<script src="javascripts/scale.fix.js"></script>
<script type="text/javascript">
   var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
   document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
   try {
      var pageTracker = _gat._getTracker("UA-56740469-1");
      pageTracker._trackPageview();
   } catch(err) {}
</script>
<div id="tip" style="display:none"></div>
</body>
</html>
